CNTO 148
|
|
CNTO 148 속성
- 저장 조건
- Store at -20°C
- 물리적 상태
- Liquid
- 색상
- Colorless to light yellow
안전
- 위험 및 안전 성명
- 위험 및 사전주의 사항 (GHS)
유해 물질 데이터 | 476181-74-5(Hazardous Substances Data) |
---|
그림문자(GHS): | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
신호 어: | Danger | ||||||||||||||
유해·위험 문구: |
|
||||||||||||||
예방조치문구: |
|
CNTO 148 C화학적 특성, 용도, 생산
개요
The proinflammatory cytokine tumor necrosis factor-alpha (TNF-α) has been implicated as the primary mediator of articular inflammation in diseases such as RA, PsA, and AS. Targeting TNF-a has been a successful strategy in the intervention of a range of immunoinflammatory disorders. Biologics have risen to the forefront of TNF-α blockade with infliximab, a chimeric monoclonal antibody (mAb), and etanercept, a fusion protein comprised of the ligand-binding segment of the soluble TNF receptor, reaching the market in the late 1990s for the initial indication of RA. Since then, their use has expanded to other diseases of inflammatory etiology, and two additional TNF-α inhibitors have joined the competition. Golimumab, a human anti-TNF-α mAb that binds to both soluble and transmembrane forms of TNF-a, is the first once-monthly subcutaneous agent to enter the market and is currently approved for the treatment of RA in combination with methotrexate (MTX), PsA alone or in combination with MTX, and AS. .용도
Treatment of allergic asthma.부작용
The most common adverse reactions, occurring with an incidence >5%, were upper respiratory tract infection and nasopharyngitis. Regarding drug interactions, live vaccines should not be administered while being treated with golimumab. As an increased risk of serious infection has been associated with concomitant use of abatacept and anakinra, combination of these drugs is not recommended. Also, golimumab treatment should not be initiated in patients with an active infection. Furthermore, patients should be warned about the higher incidence of malignancies observed with anti-TNF-a therapy and increased risks of worsening or new onset of heart failure, of exacerbation or new onset of demyelinating disease, and of hepatitis B reactivation.CNTO 148 준비 용품 및 원자재
원자재
준비 용품
CNTO 148 공급 업체
글로벌( 15)공급 업체
공급자 | 전화 | 이메일 | 국가 | 제품 수 | 이점 |
---|---|---|---|---|---|
Shanghai EFE Biological Technology Co., Ltd. | 021-65675885 18964387627 |
info@efebio.com | China | 9707 | 58 |
ShangHai Biochempartner Co.,Ltd | 17754423994 17754423994 |
2853530910@QQ.com | China | 8013 | 62 |
Alchemist-pharm chemical Technology Co. Ltd. | 0371-67991738 13783628208 |
carl@alchemist-pharm.com | China | 1877 | 58 |
Guangzhou Hongyuan Chemical Co.,Ltd | 15817493340 |
981810490@qq.com | China | 1566 | 58 |
Wuhan Chemstan Biotechnology Co., Ltd. | 027-65317797 15926423062 |
422450190@qq.com | China | 10022 | 58 |
Hubei Kele Fine Chemical Co., Ltd | 027-59101668 19945030958 |
2881924765@qq.com | China | 7984 | 58 |
Shaanxi DIDU pharmaceutical and Chemical Co., Ltd | 17691182729 18161915376 |
1046@dideu.com | China | 10011 | 58 |
Wuhan Yingnuo Pharmaceutical Technology Co., Ltd. | +86-027-59232304 15387063101 |
2881924050@qq.com | China | 9934 | 58 |
AntibodySystem | 17762345272 18162686757 |
biolab-reagents@atagenix.com | China | 9817 | 58 |
Wuhan Jingkangen Biomedical Technology Co., Ltd | 13720134139 13720134139 |
orders@jknbiochem.com | China | 5370 | 58 |
CNTO 148 관련 검색:
Follicle stimulating hormone
Secukinumab
Daratumumab
OMALIZUMAB
Dulaglutide
Trastuzumab emtansine
Ranibizumab
palivizumab
Immunoglobulin G4,anti-(human integrin R4) (human-mouse monoclonal AN100226 c4-chain),disulfide with human-mouse monoclonal AN100226 light chain,dimer
Eculizumab
Matuzumab
ticilimumab tremelimumab
Aflibercept
abciximab
Vedolizumab
Avelumab
nimotuzumab
belimumab